Ivosidenib联合阿扎胞苷治疗新诊断IDH1突变急性髓系白血病
这项开放标签多中心Ib期试验评估了口服ivosidenib 500 mg每日连续联合皮下阿扎胞苷75 mg/m2(每28天周期第1-7天)治疗不适合强化诱导化疗的新诊断IDH1突变AML患者的安全性和疗效。23例患者(中位年龄76岁)的总缓解率为78.3%,完全缓解率为60.9%,12个月生存估计为82.0%。联合治疗耐受良好,缓解深度且持久,多数完全缓解者实现mIDH1突变清除。
要点
- Ivosidenib联合阿扎胞苷在初治不适合强化疗的mIDH1 AML中总缓解率78.3%、完全缓解率60.9%。
- 治疗相关≥3级不良事件主要为中性粒细胞减少(22%)、贫血(13%)、血小板减少(13%)和QT间期延长(13%)。
- 完全缓解者中71.4%(10/14)通过BEAMing数字PCR实现骨髓单核细胞mIDH1清除。
核心结论
- Ivosidenib联合阿扎胞苷耐受良好,安全性特征与各自单药一致。
- 缓解深度且持久,多数完全缓解者实现mIDH1突变清除。
研究设计与样本
- 开放标签、多中心、Ib期试验,包括剂量探索和扩展阶段。
- 23例新诊断mIDH1 AML且不适合强化诱导化疗的患者接受ivosidenib 500 mg每日连续口服联合阿扎胞苷75 mg/m2皮下注射(每28天周期第1-7天)。
- 中位年龄76岁(范围61-88岁)。
主要发现
- 总缓解率为78.3%(18/23;95% CI 56.3%-92.5%),完全缓解率为60.9%(14/23;95% CI 38.5%-80.3%)。
- 中位随访16个月,缓解者的中位缓解持续时间未达到。
- 12个月生存估计为82.0%(95% CI 58.8%-92.8%)。
- 治疗相关≥3级不良事件发生率>10%者包括中性粒细胞减少(22%)、贫血(13%)、血小板减少(13%)和心电图QT间期延长(13%)。
- 特别关注的不良事件包括任何级别的IDH分化综合征(17%)、任何级别的心电图QT间期延长(26%)和≥3级白细胞增多(9%)。
关键数值与推荐
- 完全缓解者中,10/14例(71.4%)通过BEAMing数字PCR检测到骨髓单核细胞mIDH1清除。
- 中位治疗持续时间为15.1个月(范围0.3-32.2个月),截至2019年2月19日,10例患者仍在治疗中。
临床怎么用
- 对于不适合强化诱导化疗的新诊断mIDH1 AML患者,ivosidenib联合阿扎胞苷是一种耐受良好且缓解率高的治疗选择。
- 治疗期间需监测分化综合征、QT间期延长和血细胞减少等不良事件。
局限性
- 样本量较小(23例),为单臂Ib期试验,缺乏随机对照。
- 随访时间有限(中位16个月),长期生存获益尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML). Preclinical work suggested that addition of azacitidine to ivosidenib enhances mIDH1 inhibition-related differentiation and apoptosis. PATIENTS AND METHODS: This was an open-label, multicenter, phase Ib trial comprising dose-finding and expansion stages to evaluate safety and efficacy of combining oral ivosidenib 500 mg once daily continuously with subcutaneous azacitidine 75 mg/m2 on days 1-7 in 28-day cycles in patients with newly diagnosed mIDH1 AML ineligible for intensive induction chemotherapy (ClinicalTrials.gov identifier: NCT02677922). RESULTS: Twenty-three patients received ivosidenib plus azacitidine (median age, 76 years; range, 61-88 years). Treatment-related grade ≥ 3 adverse events occurring in > 10% of patients were neutropenia (22%), anemia (13%), thrombocytopenia (13%), and electrocardiogram QT prolongation (13%). Adverse events of special interest included all-grade IDH differentiation syndrome (17%), all-grade electrocardiogram QT prolongation (26%), and grade ≥ 3 leukocytosis (9%). Median treatment duration was 15.1 months (range, 0.3-32.2 months); 10 patients remained on treatment as of February 19, 2019. The overall response rate was 78.3% (18/23 patients; 95% CI, 56.3% to 92.5%), and the complete remission rate was 60.9% (14/23 patients; 95% CI, 38.5% to 80.3%). With median follow-up of 16 months, median duration of response in responders had not been reached. The 12-month survival estimate was 82.0% (95% CI, 58.8% to 92.8%). mIDH1 clearance in bone marrow mononuclear cells by BEAMing (beads, emulsion, amplification, magnetics) digital polymerase chain reaction was seen in 10/14 patients (71.4%) achieving complete remission. CONCLUSION: Ivosidenib plus azacitidine was well tolerated, with an expected safety profile consistent with monotherapy with each agent. Responses were deep and durable, with most complete responders achieving mIDH1 mutation clearance.
引用
- DiNardo CD, Stein AS, Stein EM, et al. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2020. PMID: 33119479. doi:10.1200/JCO.20.01632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。